TNF Pharmaceuticals Inc. Regains Compliance with Nasdaq Minimum Bid Price Rule
I'm PortAI, I can summarize articles.
TNF Pharmaceuticals Inc. has regained compliance with Nasdaq's minimum bid price requirement, confirmed on September 16, 2025. The company maintained a minimum bid price of $1.00 for 10 consecutive business days, meeting Nasdaq Listing Rule 5550 (a)(2). Executive Chairman Joshua Silverman expressed satisfaction with this achievement and emphasized the company's focus on growth and enhancing shareholder value, with further updates expected soon.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments